Inactive Instrument

Other languages Stellar Biotechnologies Inc Nasdaq

Equities

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS	06-24
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-10
Top Premarket Gainers	03-05
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-09
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-15
Top Premarket Decliners	12-13
Top Premarket Gainers	11-22
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	11-20
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	23-10-25
Top Premarket Decliners	23-10-13
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12
Sector Update: Health Care	23-10-12
Top Midday Gainers	23-10-12
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	23-10-12
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	23-10-10
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	23-09-28
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-09
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	23-06-28
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11
Edesa Biotech, Inc. to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting	23-03-16

No results for this search